About LIBERTY LIBERTY is a Phase 3, randomized, double-blind clinical trial to evaluate the safety, serum virus neutralizing antibody responses, and pharmacokinetics of VYD2311, an mRNA COVID vaccine, ...
The investigational monoclonal antibody, VYD2311, (Invivyd) met all primary and key secondary endpoints in the phase 3 LIBERTY study. It showed safety and tolerability superior to an mRNA-based ...
Yearly Covid-19 Booster Recommendations in Canada, Europe, and Australia. Although the rapid development of multiple Covid-19 vaccines in 2020 represents a major scientific, medical, and regulatory ...
As the fall approaches, it’s time to think about respiratory virus season and how to protect yourself. COVID-19 cases are already rising in most parts of the country as a late summer wave sweeps ...
SARS-CoV-2 infections have been rising in the past month — global cases increased by more than 19,000 last month compared with the previous month, according to data posted on the World Health ...
Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...
Invivyd, Inc. announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results